Acute coronary syndrome and myocardial infarction
93 results
1 - 93
Acute coronary syndrome and myocardial infarction - Coronary heart disease
- Diagnostic coronary angiography
For treatment of acute coronary syndrome, prasugrel is better than ticagrelor at preventing recurrent MIs at 1 year- Antithrombotic agents in primary health care
- Bivalirudin = abciximab + heparin for non-STEMI
Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome- Statins for acute coronary syndrome
- Signs and symptoms not helpful in diagnosis of AMI/ACS
- Early invasive therapy better for non-ST ACS
- Dyspepsia
- Intensive lipid lowering reduces mortality following ACS
- Escitalopram reduces risk of adverse cardiac events in adults with depression and acute coronary syndrome
- PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
- High-sensitivity troponin I of less than 5 ng/L has negative predictive value of 99.9% for cardiac death at 1 year
- Two-hour protocol identifies patients at low risk of ACS
- Early CT angiography for suspected acute coronary syndrome reduces further ischemic testing; no effect on long-term clinical outcomes
- Accelerated protocol identifies chest pain patients at low risk for major cardiac events
- Hyperbaric oxygen therapy for acute coronary syndrome
- Clopidogrel monotherapy more effective than aspirin to prevent coronary events after PCI with drug-eluting stents (HOST-EXAM)
- Pioglitazone does not increase cardiovascular events (PROactive)
- Adding ezetimibe to moderate-dose statin reduces nonfatal MI only (NNT = 58 for 6 years)
- Similar outcomes after PCI in hospitals with or without on-site cardiac surgery (CPORT-E)
- Statins for acute coronary syndrome
- Additional testing of limited benefit in patients with new-onset chest pain
- Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes: Cochrane systematic review
- Clopidogrel plus aspirin vs aspirin alone for preventing cardiovascular events
- High-sensitivity troponin safely reduces admissions and duration of stay in the emergency department
- Intensive versus moderate statin therapy
- Ticagrelor (Brilinta) is no better than aspirin—and may be worse—for adults after CABG
- B vitamins, fish oil do not prevent CV events
- Overuse alert: treat-to-target LDL strategy of statin dosing is noninferior to high-intensity dosing
- Mortality rate in patients with recent ACS and endoscopy is similar to that in patients with ACS and no endoscopy
- Acute abdomen in the adult
- Flu vaccine reduces risk of adverse CV events in high-risk patients
- Intensive BP control modestly decreased the likelihood of a broad composite of CV events, but with methodologic limitations
- Exercise stress test
- Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes: Cochrane systematic review
- Adding CCTA to chest pain assessment reduces likelihood of nonfatal MI (SCOT-HEART)
- 6-month clopidogrel better than 24 after stent placement (PRODIGY)
- Warfarin therapy
- Lipid lowering is beneficial for secondary prevention but not primary prevention in patients 75 years and older
- Dyspnoea
- Drug treatment for hypertension
- In patients with vascular disease, treating sleep apnea does not reduce the risk of cardiovascular events
- Acute heart failure and pulmonary oedema
- Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease
- Similar number of cardiovascular events and reduced bleeding with abbreviated dual antiplatelet therapy after PCI
- Increased readmissions and adverse events with intensification of antihypertensive regimen on hospital discharge
- Interpretation of adult ECG
- Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)
- Chronic heart failure
- SBP of 120 instead of 140 in adults 75 years or older = significant benefits and some harms (SPRINT)
- Little if any benefit to early invasive strategy for stable angina and at least moderate reversible ischemia (ISCHEMIA trial)
- SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
- Treatment of dyslipidaemias
- Final report from SPRINT: lowering SBP below 120 mm Hg decreases major adverse cardiac events and all-cause mortality
- Transfusion thresholds for guiding red blood cell transfusion
- Syncope: causes and investigations
- Management of acute atrial fibrillation
- Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events
- Overview of new ACC/AHA lipid guidelines: here we go again
- Prehospital emergency care
- For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
- ** Update Information **
- COVID-19 and other coronavirus infections